AbbVie’s Humira exclusivity loss is a missed opportunity for competitors, says analyst
US pharma major AbbVie’s (NYSE: ABBV) market leadership, driven by its flagship disease-modifying antirheumatic drug Humira (adalimumab), faced a significant test with the 2023 loss of patent protection.
Despite an anticipated competitive surge, rivals have struggled to capitalize. AbbVie's strategic shift to Skyrizi (risankizumab) and Rinvoq (upadacitinib) has solidified its position, underscoring a missed opportunity for competitors in the immunology market, says pharma analytics company GlobalData.
AbbVie has maintained a strong position within the immunology space for the past few years, largely due to the success of its anti-tumor necrosis factor (TNF) inhibitor, Humira. On December 31, 2002, the drug received its first US Food and Drug Administration (FDA) approval to treat rheumatoid arthritis in adult patients and saw $246 million in US sales the following year on market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze